OBJECTIVE: Previous studies have shown decreased levels of placenta growth factor in serum of pregnant @entity1 with @entity1468 . The aim of this study was to investigate whether levels of placenta growth factor are decreased before the clinical onset of @entity1468 , and whether placenta growth factor levels are decreased in @entity2099 complicated by @entity1592 . METHODS: From an ongoing longitudinal study, 101 plasma samples were collected from 72 pregnant @entity1 at weeks 11-21 of gestation. Placenta growth factor levels were determined retrospectively in plasma using an enzyme-linked immunosorbent assay. Correlations between plasma concentrations of placenta growth factor and pregnancy outcome were evaluated. RESULTS: Plasma samples of 72 @entity1 were analyzed. Forty-four @entity1 had no pregnancy complications, 18 developed @entity1468 , and 10 @entity1 had @entity2099 complicated by @entity1592 . Between week 17 and week 21 of pregnancy, a significantly lower level of placenta growth factor was found in plasma of @entity1 who later developed @entity1468 (n = 10), compared with control @entity2099 (n = 25, P = .004). In @entity1 with a growth-restricted baby at birth (n = 5), levels of placenta growth factor were also low. CONCLUSIONS: Our results show that plasma placenta growth factor levels are decreased before @entity1468 is clinically evident. The data suggest that placenta growth factor may be useful to determine the relative risk of developing @entity1468 and @entity1592 .

Plasma placenta growth factor levels in midtrimester XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity1592 :: ('MESH:D005317', 'Disease') :: ['intrauterine growth restriction'] @entity2099 :: ('MESH:D011254', 'Disease') :: ['pregnancies'] @entity1468 :: ('MESH:D011225', 'Disease') :: ['preeclampsia']
@entity2099 :: (MESH:D011254,Disease) :: ['pregnancies']
